Anthracycline drug targeting: Cytoplasmic versus nuclear - A fork in the road

Drug Resistance Updates

Volumn 4, Issue 3, 2001, Pages 169-177

  Lothstein, Leonard ^a   Israel, Mervyn ^a   Sweatman, Trevor W ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' (3 CYANOMORPHOLINO) 3' DEAMINODOXORUBICIN; 3' DEAMINO 3' HYDROXYDOXORUBICIN; 3' DEAMINO 3' MORPHOLINODOXORUBICIN; 3' DEAMINO 3' MORPHOLINYL 13 DEOXO 10 HYDROXYCARMINOMYCIN; ACLARUBICIN; AD 445; ANTHRACYCLINE ANTIBIOTIC AGENT; CALPHOSTIN; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; DOXORUBICIN DERIVATIVE; EPIRUBICIN; GALARUBICIN; IDARUBICIN; MEN 10746; METHOXYMORPHOLINODOXORUBICIN; MIDOSTAURIN; MORPHOLINE DERIVATIVE; N BENZYLDOXORUBICIN; N BENZYLDOXORUBICIN 14 VALERATE; N TRIFLUOROACETYLDOXORUBICIN; PIRARUBICIN; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; SABARUBICIN; STAUROSPORINE; UNCLASSIFIED DRUG; VALRUBICIN; WP 159; WP 631;

BLOOD DISEASE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL NUCLEUS; CLINICAL TRIAL; CYTOPLASM; CYTOTOXICITY; DRUG DESIGN; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR;

EID: 0035190606     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0201     Document Type: Review

References (97)

1. The anthracyclines: Will we ever find a better doxorubicin?
2. Topoisomerase poisons: Harnessing the dark side of enzyme mechanism
3. ATP-bound topoisomerase II as a target for anti-tumor drugs
4. Cardiovascular toxicity with cancer chemotherapy
5. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
6. Anthracycline metabolism and toxicity in human myocardium: Comparisons between doxorubicin, epirubicin, and a novel disaccharide analogue with a reduced level of formation and [4Fe-4S] reactivity of its secondary alcohol metabolite
7. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage
8. The role of iron in doxorubicin-induced cardiomyopathy
9. Mechanisms of anti-cancer agents: Emphasis on oxidative stress and electron transfer
10. p53 induction and apoptosis in response to radio- and chemotherapy in vivo is tumor-type-dependent
11. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals
12. Cellular thiols and reactive oxygen species in drug-induced apoptosis
13. P-glycoprotein multidrug resistance and cancer
14. P-glycoprotein as a drug target in the treatment of multidrug resistance
15. The (patho)physiological functions of the MRP family
16. Cellular resistance to anthracyclines
17. Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells
18. Reactive oxygen species-specific mechanisms of drug resistance in paraquat-resistant acute myelogenous leukemia sublines
19. Suppression of manganese superoxide dismutase augments sensitivity to radiation, hyperthermia and doxorubicin in colon cancer cell lines by inducing apoptosis
20. p53 gene status and chemosensitivity of childhood acute lymphoblastic leukemia cells to adriamycin
21. Apoptosis and the dilemma of cancer chemotherapy
22. p53-dependent regulation of MDRI gene expression causes selective resistance to chemotherapeutic agents
23. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53
24. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells
25. The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy
26. Sulfhydryl oxidation and calcium release from sarcoplasmic reticulum
27. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin
28. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol
29. The major metabolite of doxorubicin is a potent inhibitor of membrane-associated ion pumps: A correlative study of cardiac muscle with isolated membrane fractions
30. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-I in cytosolic fractions from human myocardium
31. Anthracyclines
32. Anthracydine antiobiotics in cancer therapy
33. Topoisomerase poisoning activity of novel disaccharide anthracyclines
34. Aclacinomycin A stabilizes topoisomerase I covalent complex
35. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance
36. Comparative cardiotoxicity of idarubicin and doxorubicin using the isolated perfused rat heart model
37. Epirubicin cardiotoxicity: An analysis of 469 patients with metastatic breast cancer
38. Pirarubicin-induced myocardial damage in elderly patients with non-Hodgkin's lymphoma
39. Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy
40. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy
41. Altered multidrug resistance phenotype caused by anthracycline analogues and cytosine arabinoside in myeloid leukemia
42. Idarubicin DNA intercalation is reduced by MRPI and not Pgp
43. Synthesis of Bcl-2 in response to anthracycline treatment may contribute to an apoptosis-resistant phenotype in leukemic cell lines
44. Human DNA-topoisomerases - Diagnostic and therapeutic implications for cancer
45. In vitro effect of multidrug resistance modifiers on idarubicinol efflux in blasts of acute myeloid leukemia
46. The expression of mdr-I-related gp-170 and its correlation with anthracycline resistance in renal cell carcinoma cell lines and multidrug-resistant sublines
47. Drug resistance mechanisms and MRP expression in response to epirubicin treatment in a human leukaemia cell line
48. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients
49. Selectively induced high MRP gene expression in multidrug-resistant human HL60 leukemia cells
50. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines
51. MDRI gene expression and drug resistance of AML cells
52. Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines
53. Role of the sugar moiety in the pharmacological activity of anthracyclines: Development of a novel series of disaccharide analogs
54. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity
55. Hydroxylation at C-3′ of doxorubicin alters the selected phenotype of cellular drug resistance
56. Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides
57. Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts
58. Influence of structural modifications at the 3′ and 4′ positions of doxorubicin on the drug ability to trap topoisomerase II and to overcome multidrug resistance
59. Catalytic inhibition of DNA topoisomerase II by N-benzyladriamycin (AD 288)
60. Molecular effects of paclitaxel: Myths and reality
61. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer
62. Cellular resistance to anthracyclines
63. Antigenic expression changes occurring in adriamycin resistant MCF-7 mammary carcinoma cells
64. Effect of MEN 10755, a new disaccharide analogue of doxorubicin, on sarcoplasmic reticulum Ca(2+) handling and contractile function in rat heart
65. Intensely potent morpholinyl anthracyclines
66. Degradation of the morpholino ring in the crystal structure of cyanomorpholinodoxorubicin complexed with d(CGATCG)
67. Differential single-versus double-strand DNA breakage produced by doxorubicin and its morpholinyl analogues
68. Mechanistic aspects of DNA damage by morpholinyl and cyanomorpholinyl anthracyclines
69. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II
70. Phase II trial of pre-irradiation KRN8602 (MX2) in malignant glioma patients
71. Mode of action of topoisomerase II-targeting agents at a specific DNA sequence
72. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA
73. Enzymatic and chemical footprinting of anthracycline antitumor antibiotics and related saccharide side chains
74. N-Benzyladriamycin-14-valerate and drug resistance: Correlation of anthracycline structural modifications with intracellular accumulation and distribution in multidrug resistant cells
75. N-Benzyladriamycin-14-valerate (ad 198) targets protein kinase C (PKC)-δ in 32D cells to rapidly trigger mitochondrial-dependent apoptosis independent of Bcl-2 status
76. Bisanthracycline WP631 inhibits basal and Sp I-activated transcription initiation in vitro
77. A peptide-doxorubicin 'prodrug' activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo
78. Self-immolative anthracycline prodrugs for suicide gene therapy
79. Pharmacokinetics of DA-125, a new anthracycline, after intravenous administration to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats
80. Annamycin circumvents resistance mediated by the multidrug resistance-associated protein (MRP) in breast MCF-7 and small-cell lung UMCC-I cancer cell lines selected for resistance to etoposide
81. Antitumor activity of DA-125, a novel anthracycline, in human gastric and pulmonary adenocarcinoma cells resistant to adriamycin and cisplatin
82. Testicular cytotoxicity of DA-125, a new anthracycline anticancer agent, in rats
83. Phase I clinical trial: Pharmacokinetics of a novel anthracycline, DA-125 and metabolites. Single dose study
84. Abrogation of the selectivity of adriamycin for negatively-charged phospholipids by 14-valerate sidechain substitution
85. Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding Clb domain of protein kinase C-delta
86. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length
87. Protein kinase C and phospholipase C: Bilayer interactions and regulation
88. The transition from a pharmacophore-guided approach to a receptor-guided approach in the design of potent protein kinase C ligands
89. N-benzyladriamycin-14-valerate and drug resistance: Correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells
90. Pharmacology of the receptors for the phorbol ester tumor promoters: Multiple receptors with different biochemical properties
91. Synthesis and phorbol ester-binding studies of the individual cysteine-rich motifs of protein kinase D
92. Murine cardiotoxicity assay of the mechanistically novel adriamycin analog, N-benzyladriamycin-14-valerate
93. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder
94. Substitutions at the 3′-amino of doxorubicin alter the mechanism and specificity of topoisomerase inhibition
95. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck
96. Sensitivity of human glioma U-373MG cells to radiation and the protein kinase C inhibitor, calphostin C
97. Protein kinase C inhibitor and irradiation-induced apoptosis: Relevance of the cytochrome c-mediated caspase-9 death pathway